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Abstract
Background: Unplanned care interruption (UCI) challenges effective HIV treatment. We determined the frequency
and risk factors for UCI in Nigeria.
Methods: We conducted a retrospective-cohort study of adults initiating antiretroviral therapy (ART) between
January 2009 and December 2011. At censor, patients were defined as in care, UCI, or inactive. Associations
between baseline factors and UCI rates were quantified using Poisson regression.
Results: Among 2,496 patients, 44 % remained in care, 35 % had ≥1 UCI, and 21 % became inactive. UCI rates were
higher in the first year on ART (39/100PY), than the second (19/100PY), third (16/100PY), and fourth (14/100PY) years
(p < 0.001). In multivariate analysis, baseline CD4 > 350/uL (IRR 3.21, p < 0.0001), being a student (IRR 1.95, p < 0.0001), and
less education (IRR 1.58, p = 0.001) increased risk for UCI. Fifty-five percent of patients with UCI and viral load data had HIV
viral load > 1,000 copies/ml upon return to care.
Discussion: UCI were observed in over one-third of patients treated, and were most common in the first year on ART.
High baseline CD4 count at ART initiation was the greatest predictor of subsequent UCI.
Conclusions: Interventions focused on the first year on ART are needed to improve continuity of HIV care.
Keywords: Retention, Unplanned care interruption, Gaps in care, Resource-limited setting, HIV
Background
HIV is now a treatable, chronic disease with the availabil-
ity of potent ART [1]. Accordingly, the strategic focus
guiding the global HIV response has transitioned from
acute crisis to chronic disease management [2]. Retention
in care over time has plagued HIV treatment programs
worldwide, particularly those in resource-limited settings
(RLS) [3–5].
Retention in care requires a commitment to a package
of clinical care including clinic appointments, laboratory
visits, medication pick-up, and medication adherence. The
early literature on retention in HIV care indicates startling
rates of patient loss to follow-up (LTFU) in RLS, ap-
proaching 70 % prior to ART initiation and 25-40 %
after ART initiation [5, 6]. Because many of these patients
(15-90 %) are later found to have died, LTFU has been
equated with disengagement from the entire package of
HIV care [6–9].
It is now clear that patients defined as lost to follow-up
represent many types of patients; some die, some volun-
tarily withdraw from care, others transfer care to different
treatment facilities, while others interrupt but later return
to care [10–15]. Patients with unplanned care interrup-
tions (UCI) are at increased risk for CD4 decline, uncon-
trolled viremia, opportunistic infections, and long-term
mortality [11, 13, 15–18].
The largest review of interruptions in care and treat-
ment among HIV-infected patients highlights that such
interruptions are common, occurring in approximately
25 % of patients initiated on ART [15]. This review also
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describes wide variation in definitions of care interrup-
tion ranging from 1 day to 1 year or more without treat-
ment or care [15]. Risk factors for UCI in HIV care vary in
different settings, however studies in RLS remain sparse
[11, 15, 16, 19]. Nigeria is the most populous country in
Africa, and has the second largest HIV-infected popula-
tion, behind South Africa [20, 21]. Our objective was to
determine the rates and risk factors for UCI among pa-
tients who have initiated ART in Nigeria.
Methods
Setting
This study was conducted at the Ahmadu Bello University
Teaching Hospital’s (ABUTH) HIV clinic. ABUTH is lo-
cated in a semi-urban community in the northern Nigerian
state of Kaduna, HIV prevalence in the state is 9.2 % [20,
22]. The ABUTH clinic began providing care in 2006.
In the same year, PEPFAR support commenced and
ART was provided free of charge to all eligible pa-
tients. ABUTH currently offers comprehensive HIV test-
ing and treatment to nearly 4,000 patients. During the
study period, the clinic was managed by the AIDS Preven-
tion Initiative in Nigeria (APIN), a PEPFAR-supported
NGO, which is one of the largest HIV treatment programs
in Nigeria.
Study design
We conducted a retrospective cohort study of ART eligible
patients ≥14 years of age enrolled in the ABUTH clinic,
who initiated ART between January 1, 2009 and December
31, 2011. Patients were followed through December 31,
2012 to allow for a minimum of 1-year of observation for
all patients. Women who were pregnant at enrollment or
became pregnant during the follow-up period were not
included in the analysis, as the protocol for clinic follow-up
differed between this group and the general adult popula-
tion. Upon clinic enrollment, patients received a variety of
services according to protocol including clinical evaluation,
TB symptom screening, adherence counseling, and CD4
count as well as viral load testing. Information on receipt
of adherence counseling was not available in the electronic
medical record. In the first 12 weeks after enrollment, pa-
tients were scheduled to be seen at 2, 4, 8, and 12 weeks
for adherence counseling, clinical examination, and TB
symptom screening. Subsequently, they were seen for
ART pick-up every 4 weeks, clinical examination and ad-
herence counseling every 12 weeks, and laboratory testing
(including CD4 count and HIV viral load) every 24 weeks
[23]. All data, including baseline demographic information,
clinical visits and evaluations, laboratory visits and results,
and drug pick-up visits were collected in structured data
entry forms which were uploaded to APIN’s central elec-
tronic clinical database.
Outcome measures
At study censor date (December 31, 2012) we categorized
patients into 1 of 3 mutually exclusive groups based on
their visit patterns. A visit was defined as any encou-
nter with the clinic, whether for clinical, laboratory, or
pharmacy services. Patients were defined as in care if the
time between any two consecutive visits was ≤90 days,
and the time between the last visit and censor date
was ≤180 days. Patients were defined as having an un-
planned care interruption (UCI) if the time between
any two consecutive visits was ever >90 days, but they
returned to clinic before the censor date. This defin-
ition was not dependent upon the time between the
last visit and censor date. Finally, patients were de-
fined as inactive if the time between any two consecu-
tive visits was ≤90 days, but the time between the last
visit and the censor date was >180 days. Patients known to
have transferred care or died during the follow-up period
were categorized based on their visit patterns prior to
transfer or death (i.e., such patients could not have been
classified as inactive). Under routine circumstances, an ab-
sence from the clinic of at least 90 days implied that a
patient missed three ART pick-up visits, and at least one
clinical visit. In select circumstances, clinic protocol per-
mitted dispensing of 2-month ART prescriptions to viro-
logically suppressed patients on ART for >1 year. We
chose a 90-day window to define UCI to ensure no overlap
with this select group of stably suppressed patients.
Statistical analysis
Rates of UCI and time on ART
We determined the ratio of the number of patients with
at least one UCI in the first, second, third, and fourth
years on ART; and the total person-time at risk for UCI
during each year. We calculated rates of UCI at the end
of each year on ART.
Predictors of UCI in the first year on ART
We built bivariate and multivariate Poisson regression
models to assess the association between baseline age,
sex, education, employment, TB diagnosis, CD4 count,
and enrollment year on the rate of first UCI during the
first year on ART. We focused the analysis on predictors
of UCI in the first year on ART since other studies have
linked early missed visits to mortality, and to ensure
consistent follow-up time for all patients in the analysis
[13, 16, 18]. Additionally, we recognized that patients
with UCI early after ART initiation might be different
from those who interrupt later; our goal was to investi-
gate predictors of the former. Data were censored at the
date of last visit (before first UCI or becoming inactive
from clinic) or one year after ART initiation for those
who remained in care. Covariates with associations at
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p ≤ 0.10 in the bivariate model were included in the final
multivariate model. The multivariate model was adjusted
for enrollment year to account for possible temporal
trends that might impact UCI.
Change in CD4 count before and after UCI
We conducted a Wilcoxon matched-pairs signed rank test
on available CD4 counts drawn at baseline, prior to UCI,
and within 3 months of return from UCI for patients who
interrupted care.
HIV viral load after UCI
We reported dichotomized viral loads within 3 months of
return from UCI (>1000 copies/mL vs. ≤1000 copies/mL)
for patients who interrupted care and had available data;
baseline HIV viral load testing is not routinely performed
in this population.
Statistical analysis was conducted with Stata Statistical
Software (StataCorp. 2013. Stata Statistical Software: Re-
lease 13. College Station, TX, USA).
Sensitivity analysis
There is substantial variation in how absences from HIV
care are defined in the literature [15, 24]. Consequently,
we varied the definition of UCI from 90 days to 180 days
without clinic contact in sensitivity analysis.
IRB approval
IRB approval was obtained from Partners HealthCare and
Harvard T. H. Chan School of Public Health in Boston,




Our cohort was composed of 2,496 adults who enrolled at
ABUTH and initiated ART between 2009 and 2011. Me-
dian observation time was 22.5 months [IQR 10, 36], and
total person-years accrued during follow-up was 4,717. Fe-
males made up 69 % of the cohort and the median age
was 32 years [IQR 27, 39]. Many patients (60 %) were mar-
ried, and a large majority (77 %) had at least primary edu-
cation. Sixty-three percent of patients were employed,
29 % were unemployed or retired, and 8 % were students.
Sixty-two percent of patients presented with WHO stage
3 or 4 disease, and median baseline CD4 count was 207
cells/uL3 [IQR 98, 344] prior to ART initiation. Four per-
cent of patients had TB upon enrollment (Table 1).
Twenty-four percent (n = 490/2029) of patients in the
cohort (with available baseline CD4 values) enrolled and
initiated ART with CD4 > 350 cells/uL. We conducted a
chart review to determine the reasons for ART initiation
in this group. All were documented to have met national
guideline criteria for starting ART. The indication for
treatment was advanced WHO stage (3 or 4) in 36 %,
continuation of ART for patients previously treated in 20 %,
concomitant TB in 5 %, and co-infection with Hepatitis B
virus in 3 % of patients. The indication for ART initiation
was not documented in 36 % of patients.
Patterns of care
At the end of follow-up, 44 % (n = 1,091) of patients
remained continuously in care, 35 % (n = 867) had ≥1
UCI, and 21 % (n = 538) became inactive. Data about
documented clinic transfers revealed that 4 % (n = 42)
of patients who were in care, and 3 % (n = 31) of pa-
tients with UCI later transferred out of the clinic. Of
the patients with UCI, 66 % (n = 576) had one inter-
ruption, 23 % (n = 198) had 2 interruptions, and 11 %
had ≥3 interruptions (Fig. 1). UCIs lasted a median of
132 days [IQR 102, 205] before return to clinic. Patients
remained in care a median of 114 days from enrollment
before the first interruption in care [IQR 24, 364], and a
median of 95 days [IQR 30, 238] before becoming inactive.
We observed the highest rate of UCI in the first year on
ART (39/100 PY, 95 % CI: 36–42). This decreased by more
than half in the second year on ART (19/100 PY, 95 % CI:
17–21.0) and continued to decline in the third (16/100 PY,
95 % CI: 13–19) and fourth (15/100 PY, 95 % CI: 11–20)
years on ART (Fig. 2).
Factors associated with UCI in the first year on ART
In bivariate analysis, demographic characteristics associ-
ated with increased rate of UCI were being single (IRR
1.28, p = 0.007), having no education (IRR 1.21, p = 0.080),
or primary/secondary education (IRR 1.22, p = 0.031) com-
pared to tertiary education, and being a student (IRR 1.46,
p = 0.007). Each decade increase in age was associated with
a 15 % decreased risk of UCI (IRR 0.85, p < 0.0001). Patients
who enrolled in clinic with CD4 count >350 cells/μL had
an increased risk of UCI (IRR 3.30, p < 0.0001). Baseline
CD4 count was lowest in the patients who later became in-
active [median 172 cells/μL, IQR: 74, 289], and highest in
those who later had interrupted care [median 272 cells/μL,
IQR: 144, 436]. The risk of UCI did not significantly change
with enrollment year (Table 2).
We conducted a multivariate analysis including variables
significant in the bivariate analyses. A total of 467 patients
(19 %) were excluded from the multivariate analysis due to
unknown baseline CD4 count (158/632 with and 309/1864
without a care interruption). A further 33 patients (1 %)
were excluded due to missing values for other variables in
the model. In this analysis, having a high baseline CD4
count (>350 cells/μL) was associated with the greatest
risk of UCI in the first year on ART (IRR 3.21, p < 0.001).
Students (IRR 1.95, p < 0.0001) and patients with no educa-
tion (IRR 1.58, p = 0.001) or primary/secondary education
(IRR 1.39, p = 0.005) remained at increased risk for UCI in
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the multivariate model. While not statistically significant,
there appeared to be a trend towards reduced risk of UCI
among patients who enrolled in care in 2011 compared to
those who enrolled in 2009 (IRR 0.08, p = 0.061) (Table 2).
The study results remained robust to different defini-
tions of UCI (ranging from 90 to 180 days with no clinic
contact) and inactive care (ranging from 90 days to 365 days
between study censor date and last visit date).
Table 1 Baseline demographics in a Nigerian cohort of HIV-Infected persons initiating ART between 2009 and 2011
All In care Unplanned care interruption Inactive
n = 2,496 n = 1,091 n = 867 n = 538
% N % N % N % N
Sex
Male 31 782 28 311 31 267 38 204
Female 69 1714 72 780 69 600 62 334
Median age (yrs) [IQR] 32 [27, 39] 32 [27, 40] 31.0 [26, 37] 32 [27, 40]
Marital status
Married 60 1506 64 699 59 516 54 291
Single 26 641 21 230 28 243 31 168
Widowed 14 349 15 162 13 108 15 79
Employment
Employed 63 1551 29 316 29 251 28 146
Unemployed/Retired 29 713 65 706 61 512 64 333
Student 8 201 5 63 10 94 8 44
Education
Tertiary 32 804 34 373 30 260 32 171
Primary/Secondary 45 1119 43 468 48 414 44 237
None 23 573 23 250 22 193 24 130
Relative enrolled in ABUTH clinic
No 82 2037 80 871 81 699 87 467
Yes 18 459 20 220 19 168 13 71
WHO stage baseline
1 16 312 15 151 18 119 11 42
2 22 448 23 224 24 152 18 72
3 36 734 38 381 34 219 34 134
4 26 533 24 232 24 154 37 147
Baseline CD4/uL
Median [IQR] 207 [98, 344] 193 [91, 291] 272 [144, 436] 172 [74, 289]
<50 13 269 14 125 10 63 18 81
50-100 12 247 13 119 9 61 15 67
101-200 23 457 25 227 17 116 25 114
200-350 28 566 33 297 24 162 23 107
>350 24 490 15 138 40 265 19 87
Baseline tuberculosis
Yes 4 97 4 43 4 32 4 22
Enrollment year
2009 39 970 35 379 46 400 35 191
2010 34 840 32 354 33 288 37 198
2011 27 686 33 358 21 179 28 149
IQR Inter-quartile range, ABUTH Ahmadu Bello University Teaching Hospital
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Immunologic and virologic response among patients with
unplanned care interruption
Baseline CD4 counts were available for 77 % (n = 667) of all
patients with UCI and follow up CD4 values were available
for 82 % of patients after first UCI. Two-thirds of CD4
counts were within 3 months of return to care. Among pa-
tients with UCI with CD4 data available median CD4 count
increased from 255 cells/μL [IQR 136, 429] at baseline to
358 cells/uL [IQR 185, 511, n = 590], (p < 0.0001) before the
first UCI and decreased to 329 cells/μL within 3 months of
return to clinic [IQR 194, 487, n = 459], (p = 0.0001). Viral
load data was available for 72 % (n = 620) of patients with
UCI, nearly half were within 3 months of return to care.
Fifty-five percent of viral loads obtained within 3 months of
return to care were >1000 copies/mL.
Discussion
Missed visits from HIV clinic resulting in interruptions
in HIV care, particularly in the first year on ART, are
known to be a predictor of subsequent morbidity and mor-
tality [13, 15, 16, 18]. In our study of almost 2,500 patients
who started ART in Nigeria, nearly 1 in 4 had UCI, and
Fig. 1 Summary of patient outcomes in a large HIV clinic study in Nigeria. UCI Unplanned care interruption
Fig. 2 Rates of Unplanned Care Interruption by year on ART. PY person-year, ART antiretroviral therapy
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another 1 in 5 became inactive from clinic. We found that
patients who started ART with high baseline CD4 count
had a greater than three-fold increased risk of UCI. Stu-
dents, 72 % of whom were university matriculates, had a 2-
fold increase in UCI. Additionally patients with less than
tertiary education had a 50 % increased risk of UCI.
More than half of patients with UCI for whom we had
viral load data returned to clinic with virologic failure, as
evidenced by viral load >1000 copies/mL.
There is a brief window of opportunity for clinics to iden-
tify and intervene on behalf of patients at increased risk for
poor outcomes due to missed visits. We found that patients
were generally in care for only 3 to 4 months before having
an UCI. Furthermore, 12 % of patients with UCI in this co-
hort later became inactive from clinic. While a systematic
review of data from Sub-Saharan Africa has shown that
overall attrition rates are highest in the first year on ART,
we believe this study is among the first to document that
Table 2 Predictors of unplanned care interruption in the first year on ART in a Nigerian cohort+
Bivariate analysis Multivariate analysis
IRR p value 95 % CI IRR p value 95 % CI
Sex
Female Ref
Male 1.09 0.301 0.92, 1.29
Agea 0.85 <0.0001 0.77, 0.93 1.06 0.333 0.94, 1.19
Marital status
Married Ref Ref
Single 1.28 0.007 1.07, 1.52 1.17 0.196 0.93, 1.45
Widowed 0.86 0.221 0.67, 1.10 0.82 0.174 0.61, 1.09
Employment
Unemployed Ref Ref
Employed 0.87 0.129 0.73, 1.04 1.10 0.417 0.88, 1.37
Student 1.46 0.007 1.11, 1.92 1.95 <0.0001 1.36, 2.80
Education
Tertiary Ref Ref
Primary/Secondary 1.22 0.031 1.02, 1.47 1.39 0.005 1.10, 1.75
None 1.21 0.080 0.98, 1.51 1.58 0.001 1.20, 2.09
Relative enrolled in same clinic
No Ref
Yes 0.98 0.840 0.80, 1.19
Baseline CD4/uL
<50 Ref Ref
50-100 0.85 0.446 0.55, 1.30 0.77 0.243 0.50, 1.19
101-200 0.77 0.171 0.53, 1.12 0.72 0.085 0.50, 1.05
200-350 0.85 0.355 0.59, 1.21 0.81 0.241 0.57, 1.15
>350 3.30 <0.0001 2.40, 4.54 3.21 <0.0001 2.32, 4.44
TB baseline
No Ref
Yes 1.11 0.589 0.75, 1.65
Enrollment year
2009 Ref Ref
2010 0.99 0.876 0.82, 1.18 0.88 0.251 0.71, 1.09
2011 0.94 0.510 0.77, 1.14 0.80 0.061 0.64, 1.01
ART Antiretroviral Therapy, IRR Incidence Rate Ratio
aAge is modeled in 10-year increments
+n = 2,000 with complete data on all variables in multivariate model
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UCI is also greatest in the first year on ART (39/100
person-years) [6]. In our analysis, this rate declined by
more than half after the first year on ART. Concomi-
tant with high rates of interruptions in care, multiple
studies from resource-limited settings also describe higher
early mortality among patients on ART compared to pa-
tients in resource-rich environments [25–28]. These find-
ings together underscore the importance of a rigorous
focus on early, effective retention in care for patients initi-
ating ART.
Our data did showed a possible trend towards improve-
ment in the risk of UCI over time in the context of local
and national efforts to improve retention. Nigeria’s 2010
National HIV guidelines called for “creation of effective
linkage and retention mechanisms to maximize benefits of
HIV treatment and care,” but did not provide specific rec-
ommendations for programs [23]. In 2011, the APIN net-
work instituted a patient tracking protocol at all of its
comprehensive sites, including ABUTH. APIN’s protocol
calls for a multidisciplinary outreach team to identify
patients after they miss a single clinic visit, contact them
by telephone or home visit to determine the reason for the
missed visit, and schedule a return visit. Additional follow-
up is necessary to determine the impact of interventions
such as these on retention and UCI.
Both feeling well and feeling unwell have been impli-
cated as reasons for poor clinic attendance and LTFU in
resource-limited settings [14, 15, 29]. Approximately 25 %
patients in our cohort were initiated on ART with baseline
CD4 > 350 cells/μL. Only 28 % of those were stably in care
during the follow-up period; 54 % had interrupted care,
and 18 % became inactive. These patients had a variety of
indications for initiating ART, including advanced WHO
stage, baseline TB, and concomitant hepatitis B virus in-
fection. Nonetheless, adjusting for other demographic fac-
tors and time on ART, this group still had the greatest risk
of UCI. In a systematic review of cohorts in Sub-Saharan
Africa, between 31 % and 95 % of patients who have not
yet met criteria to initiate ART are retained in care be-
tween enrollment in care and becoming ART eligible [5].
These patients would by definition have CD4 counts
above current guidelines for ART initiation. They may
feel well, and be less invested in care. Some programs have
developed pre-ART care packages to improve retention in
this group [23, 30]. Our findings, however, highlight poor re-
tention even among patients with high CD4 counts who
have already initiated ART. This has important implications
for retention efforts as HIV treatment programs
operationalize guidelines for ART initiation at higher CD4
thresholds, and some are calling for “test and treat” models
regardless of CD4 count [31–34].
Several studies have shown increased risk of LTFU
among single patients relative to their married counterparts
[35–37]. In our analysis, single patients were at increased
risk for UCI in bivariate, but not multivariate analysis.
While it is possible that single patients may have less
reliable support systems, and may be at greater risk for
stigma and disruptions in care, ethnographic studies show
that the relationship between social networks, stigma, and
disclosure are complex [38]. Some studies highlight the
importance of social networks and social capital to help
mobilize resources for and commitment to care and treat-
ment [39, 40]. On the other hand, a study from Malawi
found that 74 % of patients who defaulted from care had
not disclosed their HIV status to anyone in the household
[29]. Other studies have underscored the challenges with
trust, communication, discrimination and stigma faced by
patients in both sero-concordant and sero-discordant rela-
tionships, often making it difficult to look to a marital or
sexual partner for consistent adherence support [41–43].
These studies and others suggest that the promise of so-
cial support is balanced by fear of being ostracized mor-
ally, economically, and socially [38, 44].
We also identified a novel patient group, students, at
greater risk for inconsistent care. Nearly 3 in 4 students
in our cohort had UCI or became inactive from the
clinic. At least 1 in 10 Nigerian youth are enrolled in sec-
ondary or tertiary educational programs [45]. This age
group (15–29 year-olds) has the highest prevalence of
HIV infection, and accounts for nearly one-third of
Nigeria’s population [46, 47]. While there is a growing
body of literature suggesting poorer treatment outcomes
and retention among HIV-infected adolescents compared
to their adult counterparts, the student population has re-
ceived little attention [48, 49]. In our analysis, age was not
a significant predictor of UCI in the first year on ART,
even when categorized to compare adolescents to young
and older adults. Many reasons may contribute to incon-
sistent care among students, including challenges in tran-
sitioning from home to school, adjustment to new HIV
care providers (for those infected prior to starting univer-
sity schooling), absence of a trusted support system, and
frequent disruptions in the academic schedule by faculty
and staff strikes in Nigeria [50, 51]. During these strikes,
students may leave the campus for weeks or months to re-
turn home or to other family or friends [51]. Understand-
ing barriers to care for students is an important next step
to ensure successful clinical outcomes for this group.
The obstacles to consistent care may be different be-
tween resource-limited and resource-rich environments. In
our study patients with less than tertiary-level education
had a substantial increase in their risk of UCI. In a country
with 23 % unemployment, it is likely that tertiary education
is a proxy not only for formal education, but also or greater
individual or household resources [52]. In Nigeria and other
resource-limited settings, ART pick-up is tied directly to
the clinic. While the medications themselves may be free,
the cost of getting to the clinic or pharmacy and competing
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priorities have been identified as sometimes insurmount-
able challenges to effective adherence to care [53–55].
In our cohort, 93 % of all clinical encounters involved
ART pick-up. In contrast, in the United States and other
well-resourced environments, patients often have the op-
tion to retrieve ART prescriptions at pharmacies with con-
venient hours located close to home, or delivered directly
to the home. Ninety percent of Americans live within five
miles of a community pharmacy [56]. One qualitative study
investigating reasons for interruptions in care in Nigeria,
Tanzania, and Uganda described a level of unpredictable
chaos that routinely disturbs patients’ plans and schedules
[12]. The authors characterized this chaos as one of the un-
intended reasons for UCI. One consideration to reduce this
obstacle is more flexible ART dispensation (>30 days) to
reduce the burden of clinic visits earlier in the course
of ART. In APIN programs, longer ART prescriptions
may be made available, but typically only to patients who
are stable on ART with continued virologic suppression
after one year.
This study has several limitations. The cohort reflects
one hospital-based clinic site in Nigeria, which may not
be fully generalizable to other regions in Nigeria or other
resource-limited settings. Because of the retrospective
design, we were not able to assess reasons for UCI, in-
cluding whether some temporarily transferred care, or to
assess outcomes among patients who became inactive
from clinic. Follow-up CD4 count and viral load values
were available for only a subset of patients, and thus our
estimates of immunologic and virologic consequences of
interrupted care may be biased. We did not have infor-
mation about which patients received ongoing adher-
ence counseling, nor did we have full data about patient
deaths, and thus could not assess the relationship be-
tween unplanned care interruption and these factors.
This analysis also has several strengths. It is one of the
first African studies outside of South Africa to identify
predictors of unplanned interruptions from HIV care.
The study was set in Nigeria, where 10 % of the global
AIDS population resides [20]. Our analysis relied on the
robust electronic database of APIN, which captures pa-
tient encounters within the clinic, laboratory, and phar-
macy. We were therefore able to assess a range of clinic
encounters to investigate rates and predictors of overall un-
planned interruptions from HIV care. In addition, because
we had documentation of ART pick-up from pharmacy re-
cords, we knew that missed pharmacy visits implied
that patients were not taking ART dispensed from the
ABUTH clinic.
Conclusions
In conclusion, patients with consistent, stable engagement
in HIV care are in the minority in a large ART program in
Nigeria. Within the first four months after initiating ART,
more than half of patients interrupt care for 90 days or
more or become inactive from clinic. Given the impact of
missed visits on subsequent immunologic and virologic
compromise, as well as mortality, it is important to under-
stand the reasons for interruptions in care. In our cohort,
less educated patients, students, and those with higher
baseline CD4 count were at greatest risk. Interventions
to improve retention in care focused on high risk pa-
tients early after ART initiation are urgently needed.
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